Securian Asset Management Inc bought a new position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 6,291 shares of the medical research company’s stock, valued at approximately $587,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in shares of PRA Health Sciences by 44.2% during the second quarter. Bank of New York Mellon Corp now owns 2,197,004 shares of the medical research company’s stock worth $205,113,000 after purchasing an additional 673,202 shares during the period. Wells Fargo & Company MN raised its position in shares of PRA Health Sciences by 11.3% during the first quarter. Wells Fargo & Company MN now owns 1,048,281 shares of the medical research company’s stock worth $86,966,000 after purchasing an additional 106,456 shares during the period. Jennison Associates LLC raised its position in shares of PRA Health Sciences by 4,357.1% during the second quarter. Jennison Associates LLC now owns 625,994 shares of the medical research company’s stock worth $58,443,000 after purchasing an additional 611,949 shares during the period. OppenheimerFunds Inc. raised its position in shares of PRA Health Sciences by 6.7% during the first quarter. OppenheimerFunds Inc. now owns 504,094 shares of the medical research company’s stock worth $41,819,000 after purchasing an additional 31,587 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of PRA Health Sciences by 0.4% during the first quarter. Dimensional Fund Advisors LP now owns 444,854 shares of the medical research company’s stock worth $36,905,000 after purchasing an additional 1,593 shares during the period. Hedge funds and other institutional investors own 98.82% of the company’s stock.

In related news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of PRA Health Sciences stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $101.01, for a total value of $656,565,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.85% of the stock is currently owned by company insiders.

A number of research firms have recently commented on PRAH. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday. SunTrust Banks raised their price target on PRA Health Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, August 3rd. KeyCorp reaffirmed a “buy” rating and set a $115.00 price target on shares of PRA Health Sciences in a research report on Thursday, August 2nd. Barclays raised their price target on PRA Health Sciences from $100.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, August 2nd. Finally, Credit Suisse Group raised their price target on PRA Health Sciences from $104.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, August 2nd. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $107.00.

Shares of PRA Health Sciences stock opened at $105.40 on Friday. PRA Health Sciences Inc has a 52-week low of $73.23 and a 52-week high of $108.02. The company has a market capitalization of $6.73 billion, a P/E ratio of 29.38, a PEG ratio of 1.58 and a beta of 0.54. The company has a current ratio of 0.93, a quick ratio of 0.93 and a debt-to-equity ratio of 1.33.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, August 1st. The medical research company reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.12. PRA Health Sciences had a return on equity of 24.52% and a net margin of 4.25%. The business had revenue of $722.84 million for the quarter, compared to analyst estimates of $706.57 million. During the same quarter last year, the firm earned $0.79 EPS. PRA Health Sciences’s revenue for the quarter was up 35.4% compared to the same quarter last year. research analysts forecast that PRA Health Sciences Inc will post 3.89 earnings per share for the current year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: Leveraged Buyout (LBO) Explained

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.